Eligibility criteria for expanded access typically include having a serious or immediately life-threatening condition, no comparable or satisfactory alternative therapy options, and being unable to enroll in a clinical trial. The patient's physician must also determine that the potential benefits justify the potential risks of the investigational treatment.
